Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930794 | 1.00 | KIT (0.45) | KITPDGFRBPRMT5DPP4DPP8 | |
| SCHEMBL27469934 | 0.70 | PRMT5 (0.66) | KITPDGFRBPRMT5 | |
| SCHEMBL3920732 | 0.70 | DPP4 (0.48) | DPP4DPP8 | |
| SCHEMBL3920725 | 0.70 | DPP4 (0.48) | DPP4DPP8 | |
| SCHEMBL3922813 | 0.70 | L3MBTL1 (0.44) | MEN1KMT2A | |
| SCHEMBL3922808 | 0.70 | L3MBTL1 (0.44) | MEN1KMT2A | |
| SCHEMBL4137706 | 0.69 | DPP4 (0.47) | KITPDGFRBDPP4DPP8 | |
| SCHEMBL3922240 | 0.68 | DPP4 (0.34) | KITPDGFRBDPP4DPP8 | |
| SCHEMBL3917849 | 0.68 | DPP4 (0.48) | DPP4DPP8 | |
| SCHEMBL3932267 | 0.67 | L3MBTL1 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2007148185-A2 | SUBSTITUTED 3 -AMINO- PYRROLIDINO-4 -LACTAMS AS DPP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | KIT 3160/4885PDGFRB 910/4885PRMT5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.